NUZ neurizon therapeutics limited

Ann: Positive 8-month Interim Data from OLE Study, page-53

  1. 3,375 Posts.
    lightbulb Created with Sketch. 3196
    to be honest had the same thoughts, but the market unlikely to have read the announcement. The survival benefit is clear per the chart, whereas the ALSFR-S chart would just show the movements. I think that is why it’s left out nothing more

    If certain patients had seen a rapid decline that may not be unexpected given the sporadic nature of the disease. Removing any declining outliers would actually suggest the other patients responded even better. This is because the outliers would in effect bring down the average.

    Don’t think we need anymore detail for the moment, if a patient passed the survival graph would have dipped it didn’t. The genetic biomarker info is all part of the data pack needed for FDA and Pharma.

    Just look at the bigger picture everything seems to be going well with the OLE and gets better everyday that passes.
    Last edited by Boffin99: 19/12/24
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.0¢
Change
0.005(3.23%)
Mkt cap ! $78.76M
Open High Low Value Volume
15.5¢ 16.0¢ 15.0¢ $78.77K 503.0K

Buyers (Bids)

No. Vol. Price($)
3 240870 15.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.0¢ 377391 2
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
NUZ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.